Burn Blend is a combination of Retatrutide and Tirzepatide, designed to leverage the triple-agonist activity of investigational Retatrutide (GLP-1, GIP, and glucagon) alongside the dual-agonist activity of FDA-approved Tirzepatide (GLP-1 and GIP). This research-focused blend is studied for its potential to enhance metabolic effects, including appetite regulation, blood sugar control, and fat metabolism, by targeting multiple hormone pathways simultaneously. While preclinical and early clinical research suggests these combined actions may support weight regulation beyond either compound alone, such blends are considered experimental research compounds and are not approved therapies or standardized treatments.